- SAS Commercial Offers
- Scientific Events
SAS Offers for Commercial Sphere
PC-controlled infusion dosing of factor VIII to hemophilic patients.
Code: IMC-T-00-00002-UEFa
Institute of Experimental Pharmacology & Toxicology
Description:
The technology allows to control dosing of factor VIII (a clotting factor) to hemophilic patients over and after surgery. The technology utilizes a mathematical model of the dynamic system describing the fate (absorption, distribution, and removal) of factor FVIII in a patient, identified after administration of a test dose of this factor to the patient before surgery. The model identified in this way is patient-specific. It depends exclusively on the inherent characteristics of the patient dominant for the fate of factor VIII in the patients body and is independent on the route of the factor VIII administration.
Advantage:
In comparison to methods currently used in the clinical practice this technology not only allows to reach and maintain levels of factor VIII following treatment requirements in the patient but it allows to decrease factor VIII consumption representing a significant decrease of the price of hemophilia treatment in patients undergoing major surgery.
